Tirzepatide helps lower body weight, cardiovascular risk in diabetics

Published On 2021-10-28 10:17 GMT | Update On 2021-10-28 10:46 GMT

Tirzepatide is a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.

A new study by Prof Stefano Del Prato, MD and team has revealed that in people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, showed greater efficacy than glargine in HbA1c reduction with a lower incidence of hypoglycaemia at 52 weeks.

For more details, check out the full story on the link below:

Tirzepatide Bests Insulin Glargine In Lowering A1C, Body Weight And CV Risk In Diabetics: Lancet

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Tirzepatide helps lower body weight, cardiovascular risk in diabetics

Similar News

Earlier Diabetes Diagnosis May Be Associated with Dementia Risk: Study finds

Can Jetlag Disrupt Our Metabolism? Study Provide Insights

A Diabetes Drug May Maintain Kidney Health: Study Finds

Over 800 million people Living with Diabetes, More Than Half Not Receiving Treatment: Study Finds

Low Sugar Diet in 1st 2 Years of Life May Lower Risk of Diabetes in Adults: Study Finds

Right Turn Show - Optimal Use of Dapagliflozin and its Combinations in Specialty Care Settings

SOUL Trial Shows 14% Reduction in Cardiovascular Events with Oral Semaglutide in Type 2 Diabetes

Modified Insulin with On-Off Switch May Prevent Sudden Hypoglycemic Episodes in Diabetics: Study Finds